Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FluoroPharma Medical's total inventories for the quarter that ended in Dec. 2016 was $0.00 Mil. FluoroPharma Medical's average total inventories from the quarter that ended in Sep. 2016 to the quarter that ended in Dec. 2016 was $0.00 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. FluoroPharma Medical's Net-Net Working Capital per share for the quarter that ended in Dec. 2016 was $-0.31.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
FluoroPharma Medical (OTCPK:FPMI) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
FluoroPharma Medical's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2016 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
FluoroPharma Medical's Inventory to Revenue for the quarter that ended in Dec. 2016 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
FluoroPharma Medical Total Inventories Related Terms
FluoroPharma Medical Total Inventories Historical Data
* Premium members only.
The historical data trend for FluoroPharma Medical's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FluoroPharma Medical Total Inventories Calculation
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
FluoroPharma Medical (FPMI) has a Total Inventories of $0.00 Mil as of Dec. 2016. The total amount of inventory as recorded on a company's balance sheet. View historical data for FluoroPharma Medical and its competitors.
Is FluoroPharma Medical's Total Inventories too high?
FluoroPharma Medical's current Total Inventories is $0.00 Mil.
How does FluoroPharma Medical's Total Inventories compare to HSTC and OBMPD?
FluoroPharma Medical's Total Inventories of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for FluoroPharma Medical and its competitors. FluoroPharma Medical's current Total Inventories is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is FluoroPharma Medical stock overvalued right now?
FluoroPharma Medical (FPMI) has a current Total Inventories of $0.00 Mil. The current Total Inventories is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For FluoroPharma Medical (FPMI), the current Total Inventories is $0.00 Mil as of Dec. 2016. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
FluoroPharma Medical Inc is a us-based biopharmaceutical company. It specializes in developing and commercializing molecular imaging pharmaceuticals with initial applications in the area of cardiology. The company focuses on the development of novel cardiovascular imaging agents which detect and assess acute and chronic forms of coronary artery disease (CAD). The company's clinical-stage molecular imaging pharmaceutical product candidates are 18-F TPP (BFPET) and 18-F FCPHA (CardioPET). The 18-F TPP is designed for use in stress-testing for patients with proven CAD whereas 18-F FCPHA is a molecular imaging agent which is designed to assess myocardial blood flow and metabolism in patients with CAD. The company operates in a single segment being Biopharmaceutical research and development.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FPMI has been successfully added to your 
